DS
DYN icon

David Shaw’s Dyne Therapeutics DYN Stock Holding History

David Shaw’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
+60,161
New +$1.12M ﹤0.01% 3543
2025
Q4 		– Sell
-41,587
Closed -$526K – 4680
2025
Q3 		$526K Sell
41,587
-467,353
-92% -$5.33M ﹤0.01% 3844
2025
Q2 		$4.85M Buy
508,940
+221,287
+77% +$2.44M ﹤0.01% 2062
2025
Q1 		$3.01M Buy
287,653
+153,881
+115% +$2.2M ﹤0.01% 2302
2024
Q4 		$3.15M Buy
133,772
+60,732
+83% +$1.8M ﹤0.01% 2359
2024
Q3 		$2.62M Sell
73,040
-15,380
-17% -$612K ﹤0.01% 2483
2024
Q2 		$3.12M Buy
+88,420
New +$2.57M ﹤0.01% 2235
2023
Q2 		– Sell
-23,668
Closed -$273K – 4310
2023
Q1 		$273K Buy
23,668
+10,422
+79% +$135K ﹤0.01% 3783
2022
Q4 		$154K Buy
+13,246
New +$153K ﹤0.01% 4310
2021
Q1 		– Sell
-10,280
Closed -$216K – 4147
2020
Q4 		$216K Buy
+10,280
New +$203K ﹤0.01% 3710

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

David Shaw's DYN Position: Q2 2026 in Review

David Shaw opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 60,161 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: David Shaw previously reported a position in DYN as recently as Q3 2025.

David Shaw first reported a position in DYN in Q4 2020 and has held it in 10 quarters since. The position peaked at $4.85M in Q2 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • David Shaw held 60,161 shares of Dyne Therapeutics worth $1.34M as of Q2 2026.
  • Dyne Therapeutics was a new David Shaw position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3543 holding.
  • David Shaw first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • David Shaw's Dyne Therapeutics position peaked at $4.85M in Q2 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.